The innate immune response in the central nervous system and its role in glioma immune surveillance

Onkologie

Volumn 27, Issue 5, 2004, Pages 487-491

  Friese, M A ^a   Steinle, A ^b   Weller, M ^a,c  

^a Hertie Inst F Klin Hirnforschung   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Brain; Glioma; Immunology; NK cells; NKG2D

Indexed keywords

HLA G ANTIGEN; PEPTIDE; TRANSFORMING GROWTH FACTOR BETA;

CANCER INVASION; CENTRAL NERVOUS SYSTEM; COMPLEMENT SYSTEM; CYTOKINE RELEASE; GLIOMA; GLIOMA CELL; GRANULOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MACROPHAGE; NATURAL KILLER CELL; NONHUMAN; REVIEW;

EID: 10844262411     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080371     Document Type: Review

References (28)

1. Medzhitov R, Janeway CA Jr.: Decoding the patterns of self and nonself by the innate immune system. Science 2002;296:298-300.
2. Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1:135-145.
3. Natarajan K, Dimasi N, Wang J, Mariuzza RA, Margulies DH: Structure and function of natural killer cell receptors: Multiple molecular solutions to self, nonself discrimination. Annu Rev Immunol 2002;20:853-885.
4. Raulet DH: Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003;3:781-790.
5. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L: Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001;19:197-223.
6. Matzinger P: The danger model: A renewed sense of self. Science 2002;296:301-305.
7. Shi Y, Evans JE, Rock KL: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003;425:516-521.
8. Nguyen MD, Julien JP, Rivest S: Innate immunity: The missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci 2002;3:216-227.
9. van Beek J, Elward K, Gasque P: Activation of complement in the central nervous system: Roles in neurodegeneration and neuroprotection. Ann N Y Acad Sci 2003;992:56-71.
10. Backstrom E, Chambers BJ, Ho EL, Naidenko OV, Mariotti R, Fremont DH, Yokoyama WM, Kristensson K, Ljunggren HG: Natural killer cell-mediated lysis of dorsal root ganglia neurons via RAE1/NKG2D interactions. Eur J Immunol 2003;33:92-100.
11. Hickey WF: Leukocyte traffic in the central nervous system: The participants and their roles. Semin Immunol 1999;11:125-137.
12. Serafini B, Columba-Cabezas S, Di Rosa F, Aloisi F: Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis. Am J Pathol 2000;157:1991-2002.
13. Aloisi F, Ria F, Columba-Cabezas S, Hess H, Penna G, Adorini L: Relative efficiency of microglia, astrocytes, dendritic cells and B cells in naive CD4+ T cell priming and Th1/Th2 cell restimulation. Eur J Immunol 1999;29:2705-2714.
14. Neumann H: Control of glial immune function by neurons. Glia 2001;36:191-199.
15. Aloisi F: Immune function of microglia. Glia 2001;36:165-179.
16. Weller M, Thomas DGT: Primary tumors of the central and peripheral nervous system; in Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C (eds): Course and Treatment of Neurological Disorders, ed 2. San Diego, CA, Academic Press, 2003, pp 827-863.
17. Schweitzer T, Vince GH, Herbold C, Roosen K, Tonn JC: Extraneural metastases of primary brain tumors. J Neurooncol 2001;53:107-114.
18. Gorter A, Meri S: Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today 1999;20:576-582.
19. Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF, Meri S: Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol 2000;164:6075-6081.
20. Weller M, Fontana A: The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res Brain Res Rev 1995;21:128-151.
21. Gorelik L, Flavell RA: Transforming growth factorbeta in T-cell biology. Nat Rev Immunol 2002;2:46-53.
22. Walker PR, Calzascia T, Dietrich PY: All in the head: Obstacles for immune rejection of brain tumours. Immunology 2002;107:28-38.
23. Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Bornemann A, Meyermann R, Weiss EH, Melms A, Weller M: A functional role of HLA-G expression in human gliomas: An alternative strategy of immune escape. J Immunol 2002;168:4772-4780.
24. Wischhusen J, Jung G, Radovanovic I, Beier C, Steinbach JP, Rimner A, Huang H, Schulz JB, Ohgaki H, Aguzzi A, Rammensee HG, Weller M: Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res 2002;62:2592-2599.
25. Hermisson M, Strik H, Rieger J, Dichgans J, Meyermann R, Weller M: Expression and functional activity of heat shock proteins in human glioblastoma multiforme. Neurology 2000;54:1357-1365.
26. Parney IF, Farr-Jones MA, Chang LJ, Petruk KC: Human glioma immunobiology in vitro: Implications for immunogene therapy. Neurosurgery 2000;46:1169-1177.
27. Friese MA, Platten M, Lutz SZ, Naumann U, Aulwurm S, Bischof F, Buhring HJ, Dichgans J, Rammensee HG, Steinle A, Weller M: MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res 2003;63:8996-9006.
28. Saito T, Tanaka R, Yoshida S, Washiyama K, Kumanishi T: Immunohistochemical analysis of tumorinfiltrating lymphocytes and major histocompatibility antigens in human gliomas and metastatic brain tumors. Surg Neurol 1988;29:435-442.